文献速递临床试验与 GCP流行病学与生物统计

羧基麦芽糖铁治疗妊娠晚期贫血:一项随机对照试验

Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.
PubMed 文献 · Nat Med · 2025-01-06

在马拉维南部产前门诊开展的开放标签个体随机试验纳入590名妊娠27-35周、毛细血管血红蛋白<10.0 g/dl的妇女,比较羧基麦芽糖铁(FCM)与标准治疗。FCM组贫血比例46.7%(126/270)低于标准治疗组67.3%(170/271),PR 0.74(95%CI 0.64, 0.87),P=0.0002;出生体重组间无差异。

要点

  • FCM组妊娠36周或分娩时贫血比例为46.7%(126/270),标准治疗组为67.3%(170/271)。
  • FCM组较标准治疗组贫血比例降低,PR 0.74(95%CI 0.64, 0.87),P=0.0002。
  • 两组出生体重无差异,平均差10.9 g(95%CI -65.7, 87.5 g),P=0.78;未发生严重输注相关反应。

核心结论

  • 在马拉维妊娠晚期妇女中,FCM有效且安全地降低了分娩前贫血。

研究设计与样本

  • 在马拉维南部产前门诊开展的开放标签、个体随机试验,纳入590名妊娠27-35周、毛细血管血红蛋白<10.0 g/dl的妇女。

主要发现

  • 主要时间点FCM组贫血126/270(46.7%),标准治疗组170/271(67.3%),PR 0.74(95%CI 0.64, 0.87),P=0.0002。
  • 出生体重组间平均差10.9 g(95%CI -65.7, 87.5 g),P=0.78。
  • 未发生严重输注相关反应,两组不良事件无差异。

关键数值与推荐

  • FCM组:20 mg kg-1,最高1,000 mg,入组时一次给药。
  • 标准治疗组:元素铁60 mg,每日两次,共90天。
  • 主要结局为妊娠36周或分娩时(以先发生者为准)母体贫血和新生儿出生体重。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over 46% of African pregnant women are anemic. Oral iron is recommended but often suboptimal, particularly late in pregnancy. Intravenous ferric carboxymaltose (FCM) could treat anemia in women in the third trimester in sub-Saharan Africa. In an open-label, individually randomized trial in antenatal clinics in southern Malawi, we randomized 590 women at 27-35 weeks of gestation with capillary hemoglobin <10.0 g dl-1 to FCM (20 mg kg-1 up to 1,000 mg, once at enrollment) or standard of care (60 mg elemental iron, twice daily for 90 days). Participants and their infants were followed to 4 weeks postpartum. Primary outcomes were maternal anemia at 36 weeks' gestation or delivery (whichever occurred first) and neonatal birthweight. At the primary timepoint, 126 of 270 (46.7%) of women in the FCM group were anemic, compared to 170 of 271 (67.3%) women in the standard-of-care group (PR, 0.74 (95% CI 0.64, 0.87); P = 0.0002). There was no difference between groups in birthweight (mean difference 10.9 g (-65.7, 87.5 g); P = 0.78). No serious infusion-related reactions occurred, and there were no differences in adverse events between groups. In Malawian women in late pregnancy, FCM effectively and safely reduced anemia before childbirth. Australia New Zealand Clinical Trial registration: ANZCTR12621001239853.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Pasricha SR, Moya E, Ataíde R, et al. Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial. Nat Med. 2025. PMID: 39762420. doi:10.1038/s41591-024-03385-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。